Lexaria Bioscience Regains Nasdaq Compliance, Stabilizing Listing
TipRanks (Mon, 17-Aug 1:06 PM ET)
Lexaria Enters a Material Transfer Agreement With PegBio
ACCESS Newswire (Thu, 13-Aug 9:00 AM ET)
Lexaria Announces Effective Date for Reverse Stock Split
ACCESS Newswire (Thu, 30-Jul 11:00 AM ET)
Lexaria Updates Business Development
ACCESS Newswire (Mon, 6-Jul 9:10 AM ET)
Lexaria's Human Study GLP-1-H26-7 Has Begun Dosing on Schedule
ACCESS Newswire (Thu, 25-Jun 9:10 AM ET)
Lexaria's Animal Study GLP-1-A26-1 Has Begun Dosing on Schedule
ACCESS Newswire (Tue, 23-Jun 9:25 AM ET)
GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to Expand
ACCESS Newswire (Wed, 17-Jun 9:25 AM ET)
Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway
ACCESS Newswire (Tue, 9-Jun 9:25 AM ET)
ACCESS Newswire (Wed, 3-Jun 9:25 AM ET)
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
Lexaria Bioscience Corp. trades on the NASDAQ stock market under the symbol LEXX.
As of August 21, 2026, LEXX stock price declined to $10.91 with 8,098 million shares trading.
LEXX has a beta of -0.00, meaning it tends to be less sensitive to market movements. LEXX has a correlation of 0.00 to the broad based SPY ETF.
LEXX has a market cap of $18.04 million. This is considered a Sub-Micro Cap stock.
Last quarter Lexaria Bioscience Corp. reported $0 in Revenue and -$.08 earnings per share. This fell short of revenue expectation by $-20,000 and missed earnings estimates by -$.02.
In the last 3 years, LEXX traded as high as $102.75 and as low as $4.21.
The top ETF exchange traded funds that LEXX belongs to (by Net Assets): VXF.
LEXX has underperformed the market in the last year with a return of -7.4%, while SPY returned +21.7%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in LEXX shares. However, LEXX has outperformed the market in the last 3 month and 2 week periods, returning +20.2% and +107.1%, while SPY returned +3.4% and -1.0%, respectively. This indicates LEXX has been having a stronger performance recently.
LEXX support price is $10.09 and resistance is $12.45 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LEXX shares will trade within this expected range on the day.
